U.S. Wireless Telecom Stock News

NYSE:DCOM
NYSE:DCOMBanks

Is Dime Commercial Bancshares (DCOM) Undervalued As Q2 Earnings Beat And Buybacks Return?

Dime Commercial Bancshares (DCOM) is back in focus after second quarter 2026 results exceeded revenue expectations, supported by business loan growth and disciplined deposit cost management, alongside plans to restart share repurchases in Q3. See our latest analysis for Dime Commercial Bancshares. The stronger Q2 showing comes after a period of solid momentum for Dime Commercial Bancshares, with the share price at $40.81 and a 36.63% year to date share price return, alongside a 46.80% total...
NasdaqGS:DLO
NasdaqGS:DLODiversified Financial

What DLocal (DLO)'s ACI Worldwide Payments Orchestration Deal Means For Shareholders

ACI Worldwide recently announced a partnership with dLocal that plugs dLocal’s local payment network into ACI’s Payments Orchestration Platform, initially enabling global merchants to access Pix, PicPay, Mercado Pago and NuPay in Brazil, plus Mercado Pago, OXXO and SPEI in Mexico, with further rollout planned across Argentina, Chile, Colombia and Peru. By embedding dLocal’s regional payment rails into ACI’s orchestration, global merchants can use a single integration to offer preferred local...
NYSE:BLCO
NYSE:BLCOMedical Equipment

Is Bausch + Lomb (BLCO) Undervalued As EyeGility Launch And Earnings Draw Focus?

Bausch + Lomb (BLCO) is drawing fresh attention after two linked catalysts. The company just launched its EyeGility Inserter in the U.S., and investors are watching closely ahead of this week's earnings report. See our latest analysis for Bausch + Lomb. The market reaction around the EyeGility launch and upcoming earnings has come alongside a 90-day share price return of 8.28%, while the 1-year total shareholder return of 13.38% contrasts with a 3-year total shareholder return that declined...
NYSE:AGRO
NYSE:AGROFood

Adecoagro (AGRO) Faces A Valuation Split, Is It A Bargain Or Fully Priced?

Adecoagro stock performance snapshot Adecoagro (AGRO) has seen mixed share price moves recently, with the stock down about 2% over the past day and 7% over the past week, but up roughly 7% over the past month. See our latest analysis for Adecoagro. At a share price of $10.04, Adecoagro has seen recent momentum cool, with the share price return declining 30.37% over the past 90 days, while the 1-year total shareholder return of 11.68% still reflects a positive longer-term outcome. If...
NYSE:HRI
NYSE:HRITrade Distributors

Herc Holdings (HRI) Stock Price Faces A 101x P E Reality Check

Herc Holdings stock just took a punch, sliding about 7% in a single session, while the latest earnings tell a far more mixed story than that one day move suggests. Q2 equipment rental revenue reached US$1.2b and net income landed at US$19m. That is a modest profit on a large revenue base, not a collapse. The real headline is the squeeze between a high trailing P/E of 101.1x and thin 1% net margins, even after reported earnings over the last year more than doubled. The market appears focused...
NasdaqGS:CECO
NasdaqGS:CECOMachinery

CECO Environmental (CECO) Stock Could Be 37% Undervalued On Recovery Hopes

CECO Environmental stock has delivered very strong gains over the past few years, yet its recent pullback and current checks suggest the market price still sits at a discount to what an intrinsic value model implies. That mix of a big historical return and an apparent valuation gap is what investors now have to weigh. CECO Environmental has returned about 8.3x over the past 5 years, which puts recent share price weakness into the context of a very strong longer term run. Expectations for...
NasdaqGM:GHRS
NasdaqGM:GHRSPharmaceuticals

GH Research (GHRS) Stock Looks Stretched On Its 111% YTD Run

GH Research stock has surged 111.2% year to date, yet its valuation checks indicate the shares do not screen as a clear bargain. Investors are weighing that strong run against signals that the stock may already be pricing in a lot of good news. Year to date, GH Research is up 111.2%, which puts extra focus on whether recent gains are supported by fundamentals. Optimism around GH001 after key clinical milestones and sector attention following Eli Lilly’s acquisition of Atai Life Sciences can...
NYSE:SO
NYSE:SOElectric Utilities

Southern (SO) Launches Moody Battery System As Georgia Storage Push Tops 3,000 MW

Georgia Power has commissioned the Moody Battery Energy Storage System in Georgia. The project is part of a broader plan for more than 3,000 MW of grid-scale battery storage across the state. These developments expand Southern Company’s (NYSE:SO) energy storage footprint and support grid reliability. For investors following Southern Company, the new Moody Battery Energy Storage System adds another piece to the story around grid modernization and renewable integration. Georgia Power’s...
NasdaqGS:TTWO
NasdaqGS:TTWOEntertainment

Take Two Interactive Software (TTWO) Seeks Shareholder Backing To Limit Officer Liability

Take-Two Interactive Software (NasdaqGS:TTWO) has proposed an amendment to its Certificate of Incorporation to limit certain officer liability, as permitted under Delaware law. The Board is asking shareholders to approve an Officer Exculpation Amendment that would affect how direct shareholder claims, including class actions, can be brought against specific executives. The proposal does not cover breaches of loyalty, bad faith, intentional misconduct, or improper personal gain, and focuses...
NYSE:NSC
NYSE:NSCTransportation

Norfolk Southern (NSC) Gets Canadian National Backing For Union Pacific Merger

Canadian National agreed not to oppose the pending Union Pacific and Norfolk Southern (NYSE:NSC) merger. The companies entered a Memorandum of Understanding to expand cross network connectivity across North America. The understanding includes broader operating rights for Canadian National across routes linked to Norfolk Southern and Union Pacific. Norfolk Southern is one of the major Class I railroads in the United States and plays a central role in freight movements across the eastern part...
NasdaqGS:CDNS
NasdaqGS:CDNSSoftware

Cadence Design Systems (CDNS) Stock Catches Up To Rising AI Backlog

Cadence Design Systems stock barely flinched after earnings. Shares were up about 1.8% to US$344.72 by the close, even as the company posted what looks like one of its cleanest quarters in years. Revenue landed at US$1.584b with non GAAP operating margin at 45.5%, powered by heavy demand for chip design and verification tools tied to artificial intelligence. The real story for long term investors is not today’s modest price move. It is the raised full year outlook and an US$8.1b backlog that...
NYSE:WES
NYSE:WESOil and Gas

Western Midstream Partners (WES) Stock Looks Cheap Relative To Fair Value

Western Midstream Partners has delivered very strong returns over the past few years, and the stock now trades with an undervalued signal on market multiples while the broader valuation checks point to a more mixed picture. For investors, the question is whether the recent share price strength still leaves enough valuation support. Western Midstream Partners has returned about 267.2% over the past 5 years, which puts long term holders in a strong position and raises the bar for any new...
NYSE:DIS
NYSE:DISEntertainment

Disney Stock And India Streaming Shift What Investors Should Watch

India’s sports scene is shifting fast as Wimbledon’s India focused push, rising tennis viewership and growing sponsorship interest draw more attention to how streaming platforms and advertisers reach premium urban audiences. That kind of change can help some stocks and squeeze others, depending on how exposed they are to this news and how they earn their revenue. This article breaks down three India Sports Engagement Stocks Linked to Streaming and Sponsorship Shifts, with one that appears...
NasdaqGS:LCID
NasdaqGS:LCIDAuto

Rivian Stock And 2 Luxury EV Picks With A U.S. Edge

The latest move from Audi to push deeper into the U.S. luxury SUV market with its new Q9, SQ9 and refreshed Q3 and Q7 ranges is a reminder that tariffs, incentives and product mix can matter as much as brand strength. Audi’s lack of U.S. manufacturing and the recent 17% sales decline in the first half of 2026 underline how quickly conditions can shift. For investors looking at luxury automobile manufacturers exposed to this news, the goal is to separate potential beneficiaries from those...
NYSE:ARLO
NYSE:ARLOElectronic

Arlo (ARLO) Stock Looks Stretched Even With Cash Flow Upside

Arlo Technologies has delivered a 129.9% share price gain over the past 5 years, yet its current valuation picture is mixed, with an intrinsic value estimate from a Discounted Cash Flow (DCF) model pointing to upside while earnings based multiples look less generous. At the same time, the stock trades at US$14.23 with a value score that does not clearly place it in either the bargain or expensive camp. Over 5 years, Arlo Technologies has returned 129.9%, which puts the recent share price in...
NYSE:KRC
NYSE:KRCOffice REITs

Kilroy Realty (KRC) Stock Yield Beckons Even As FFO Shrinks

Kilroy Realty stock slipped about 1.9% to US$38.66 after its Q2 report, which keeps the 7 day move slightly in the red but leaves the 90 day run still firmly positive. The headline from this quarter is a profit squeeze. Funds From Operations per share, the core yardstick for office real estate investment trusts, printed at US$0.93, well below where it sat in mid 2025. Net income for the quarter came in at US$19.9m, a sharp step down from last year’s peaks. Short term traders are reacting to...
NYSE:AXTA
NYSE:AXTAChemicals

Axalta (AXTA) Stock Climbs As Record Margins Meet Softer EPS

Traders just marked Axalta Coating Systems up roughly 5% in a single session, yet the real story sits inside the margin sheet. Q2 brought record adjusted earnings before interest, taxes, depreciation and amortization of US$305 million and a Q2 high adjusted EBITDA margin of 22.7%. The question is whether this jump in the stock is simply momentum or a rational reprice of a coatings business that is squeezing more profit out of each dollar of sales. Is Axalta Coating Systems trading at a...
NasdaqGS:MMYT
NasdaqGS:MMYTHospitality

MakeMyTrip (NasdaqGS:MMYT) Stock Rich Valuation Meets Thin Profit Margins

MakeMyTrip stock edged up 2.6% to US$53.72 after earnings, a modest move for a company priced on big growth expectations and a trailing P/E near 97x. The headline this quarter is not the share price pop. It is the strain between rich valuation, a thinner net profit margin of 5% over the last year and weak interest coverage. Investors are being asked to pay well above an estimated cash flow value for MakeMyTrip while accepting a business that currently converts far less of its large booking...
NasdaqGS:INCY
NasdaqGS:INCYBiotechs

Incyte (INCY) Stock Rallies As Profit Strength Fuels Diversification Debate

Incyte stock just jumped 9.3% in a single session, yet the real story is not the share price spike. The company delivered what the market has been waiting for in biotech, with revenue for Q2 2026 reaching US$1.67b and basic earnings per share at US$2.92. The one day move reflects investors suddenly pricing in a business that now appears more profitable and more diversified than it did even a few quarters ago. Impressed by Incyte’s Q2 2026 earnings strength but want more stocks that pair solid...
NasdaqGS:FIBK
NasdaqGS:FIBKBanks

Stronger Earnings and Larger Buyback Authorization Might Change The Case For Investing In First Interstate BancSystem (FIBK)

In July 2026, First Interstate BancSystem reported second-quarter 2026 net income of US$83.9 million and diluted earnings per share of US$0.87, while also disclosing higher net loan charge-offs of US$9.7 million and announcing a US$0.47 quarterly dividend. Over the same period, the board completed a share repurchase of approximately 7.98 million shares and expanded its buyback authorization to US$450 million, signalling continued use of capital returns alongside board refreshment with two...
NasdaqGS:IRTC
NasdaqGS:IRTCMedical Equipment

iRhythm Holdings (IRTC) Could Be 34% Undervalued Following Its Recent Rebound

iRhythm Holdings (IRTC) is back on investor radars after recent trading, with the stock closing at US$117.37. The move comes against a backdrop of mixed short and longer term share price performance. See our latest analysis for iRhythm Holdings. The strong 1 day share price return of 4.65% and 7 day share price return of 7.68% come after a weaker run, with the year to date share price return down 33.02% and the 1 year total shareholder return down 14.18%. However, the 5 year total shareholder...
NYSE:MCB
NYSE:MCBBanks

Does Metropolitan Bank Holding (MCB) Raising Its Dividend Reflect Strategic Confidence or Limited Reinvestment Options?

Metropolitan Bank Holding Corp. recently reported its second-quarter 2026 results, with net interest income rising to US$90.45 million and net income edging up to US$19.22 million, while basic earnings per share from continuing operations eased to US$1.55 from US$1.78 a year earlier. Across the first half of 2026, the bank’s net income increased to US$50.65 million and diluted earnings per share from continuing operations reached US$4.40, alongside a board-approved quarterly dividend...
NYSE:HSY
NYSE:HSYFood

Hershey Stock And Other Staples Picks For Investors Seeking Steadier Ground

Tech stocks are under pressure after a sharp global semiconductor sell off, yet many investors are looking at the other side of their portfolios. Large consumer staples stocks can sometimes offer a steadier ride when chip stocks swing sharply. This article focuses on three companies from a Defensive Consumer Staples Stocks screener that appear closely exposed to the current news backdrop, whether through their role in everyday spending or their perceived lower risk profile. You will see how...
NasdaqCM:OTLK
NasdaqCM:OTLKBiotechs

Outlook Therapeutics (OTLK) Is Down 36.3% After First FDA‑Approved Ophthalmic Bevacizumab Win - What's Changed

Outlook Therapeutics recently received U.S. FDA approval for LYTENAVA (bevacizumab‑vikg) to treat neovascular (wet) age-related macular degeneration, making it the first and only FDA‑approved ophthalmic bevacizumab in the U.S. retina market. This approval, which the company believes qualifies LYTENAVA for 12 years of Reference Product Exclusivity under the Biologics Price Competition and Innovation Act, positions Outlook Therapeutics in an approximately US$8.50 billion annual U.S. anti‑VEGF...